- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02600377
A Series of Systematic Reviews and Meta-analyses of the Effect of Vegetarian/Vegan Diets on Cardiometabolic Risk
Effect of Vegetarian/Vegan Diets on Cardiometabolic Risk: Systematic Reviews and Meta-analyses of Randomized Controlled Dietary Trials to Provide Evidence-based Guidance for Nutrition Guidelines Development
Study Overview
Detailed Description
Background: Vegetarian and/or vegan dietary patterns have been shown in prospective cohort and cross-sectional studies to be associated with lower diabetes risk and all-cause mortality. Evidence from systematic reviews and meta-analyses of controlled trials also suggest that vegetarian diets may be beneficial for glycemic control, blood lipids, weight loss, and blood pressure. On the contrary, evidence from previous meta-analyses of prospective cohort studies, as well as more recent prospective cohort studies have shown that diets higher in animal protein, specifically in red meat, are associated with an increased incidence of T2D. The effect of following a vegetarian/vegan dietary pattern on cardiometabolic risk factors in individuals with diabetes is less clear. Furthermore, not all diabetes guidelines recommend following a vegetarian and/or vegan dietary pattern for the management of diabetes or they provide a low-grade evidence rating.
Need for proposed research: High quality systematic reviews and meta-analyses of randomized controlled trials represent the highest level of evidence to support dietary guidelines and public health policy development. As dietary guidelines and public health policy have shifted toward food and dietary-pattern based recommendations, there is a need for systematic reviews and meta-analyses comparing the role of vegetarian/vegan diets in the prevention and management of diabetes.
Objective: To improve evidence-based guidance for diabetes guidelines and public health policy development, the investigators will conduct a series of systematic reviews and meta-analyses of the effects of vegetarian/vegan diets on cardiometabolic risk factors in individuals with diabetes including measures of (1) glycemic control, (2) blood lipids, (3) adiposity and (4) blood pressure.
Design: Each systematic review and meta-analysis will be conducted according to the Cochrane Handbook for Systematic Reviews of Interventions and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).
Data sources: MEDLINE, EMBASE, and The Cochrane Central Register of Controlled Trials (Clinical Trials; CENTRAL) will be searched using appropriate search terms supplemented by manual searches of references of included studies.
Study selection: Dietary randomized controlled trials conducted in humans with a follow-up duration ≥ 3 weeks investigating the effect of vegetarian/vegan diets on measures of (1) glycemic control, (2) blood lipids, (3) adiposity, and (4) blood pressure will be included. Studies that are not conducted in humans, not randomized, have an acute feeding design (<3 weeks), lack a suitable control (non-isocaloric) and/or do not report viable endpoint data will not be included.
Data extraction: Two or more investigators will independently extract relevant data and assess risk of bias using the Cochrane Risk of Bias Tool. All disagreements will be resolved by consensus. Standard computations and imputations will be used to derive missing variance data.
Outcomes: The proposed syntheses will each assess a set of outcomes related to a different area of cardiometabolic risk: (1) glycemic control (HbA1c, fasting glucose, fasting insulin), (2) blood lipids (LDL-C, non-HDL-C, HDL-C, triglycerides), (3) adiposity (body weight, BMI, waist circumference), (4) blood pressure (systolic and diastolic blood pressure).
Data synthesis: Separate pooled analyses will be conducted for each area of cardiometabolic control using the Generic Inverse Variance method. Random-effects models will be used even in the absence of statistically significant between-study heterogeneity, as they yield more conservative summary effect estimates in the presence of residual heterogeneity. Exceptions will be made for the use of fixed-effects models where there is <5 included trials irrespective of heterogeneity or small trials are being pooled with larger more precise trials in the absence of statistically significant heterogeneity. Paired analyses will be applied to all crossover trials. Heterogeneity will be tested by Cochran's Q statistic and quantified by the I2 statistic. To explore sources of heterogeneity, the investigators will conduct sensitivity analyses, in which each study is systematically removed. If there are >=10 studies, then the investigators will also explore sources of heterogeneity by a priori subgroup analyses by study design (parallel or crossover), follow-up duration (<12 weeks or ≥12 weeks), comparator diet, baseline measurements, risk of bias and diabetes duration. Significant unexplained heterogeneity will be investigated by additional post hoc subgroup analyses (e.g. age, sex, level of feeding control [metabolic, supplemented, dietary advice], washout in crossover trials, energy balance of the background diet, composition of the background diet [total % energy from fat, carbohydrate, protein], change in cholesterol intake, change in glycemic index, etc.). Meta-regression analyses will assess the significance of categorical and continuous subgroups analyses. When >=10 studies are available, publication bias will be investigated by inspection of funnel plots and formal testing using the Egger and Begg tests. If publication bias is suspected, then the investigators will attempt to adjust for funnel plot asymmetry by imputing the missing study data using the Duval and Tweedie trim and fill method.
Evidence assessment: The strength of the evidence for each outcome will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE).
Knowledge translation plan: The results will be disseminated through interactive presentations at local, national, and international scientific meetings and publication in high impact factor journals. Target audiences will include the public health and scientific communities with interest in nutrition, diabetes, obesity, and cardiovascular disease. Feedback will be incorporated and used to improve the public health message and key areas for future research will be defined. Applicant/Co-applicant Decision Makers will network among opinion leaders to increase awareness and participate directly as committee members in the development of future guidelines.
Significance: The proposed project will aid in knowledge translation related to the role of vegetarian/vegan diets in the prevention and management of diabetes, strengthening the evidence-base for guidelines and improving health outcomes by educating healthcare providers and patients, stimulating industry innovation, and guiding future research design.
Study Type
Enrollment (Anticipated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Dietary trials in humans
- Randomized treatment allocation
- ≥3 weeks
- Suitable control (i.e. isocaloric diet that is not vegetarian or vegan)
- Viable endpoint data
Exclusion Criteria:
- Non-human studies
- Non-randomized treatment allocation
- <3 weeks
- Lack of a suitable control (i.e. non-isocaloric)
- No viable endpoint data
Study Plan
How is the study designed?
Design Details
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
HbA1c
Time Frame: Up to 1.5-years
|
Up to 1.5-years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Fasting glucose
Time Frame: Up to 1.5-years
|
Up to 1.5-years
|
Fasting insulin
Time Frame: Up to 1.5-years
|
Up to 1.5-years
|
LDL-cholesterol
Time Frame: Up to 1.5-years
|
Up to 1.5-years
|
non-HDL-cholesterol
Time Frame: Up to 1.5-years
|
Up to 1.5-years
|
HDL-cholesterol
Time Frame: Up to 1.5-years
|
Up to 1.5-years
|
Triglycerides
Time Frame: Up to 1.5-years
|
Up to 1.5-years
|
Body weight
Time Frame: Up to 1.5-years
|
Up to 1.5-years
|
Body mass index (BMI)
Time Frame: Up to 1.5-years
|
Up to 1.5-years
|
Waist circumference
Time Frame: Up to 1.5-years
|
Up to 1.5-years
|
Systolic blood pressure
Time Frame: Up to 1.5-years
|
Up to 1.5-years
|
Diastolic blood pressure
Time Frame: Up to 1.5-years
|
Up to 1.5-years
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- Vegetarian diets 2015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
-
University of RoehamptonRecruitingType2 Diabetes Mellitus | Pre DiabetesUnited Kingdom
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
Clinical Trials on Vegetarian diet
-
Radboud University Medical CenterRecruitingMyocardial InfarctionNetherlands
-
Azienda Ospedaliero-Universitaria CareggiCompleted
-
Columbia UniversityTata Memorial HospitalUnknown
-
Rosa AspalterUniversity Hospital RegensburgCompleted
-
Edith Cowan UniversityRoyal Perth Hospital; Fiona Stanley Fremantle Hospitals Group; St John of God...CompletedInflammatory Bowel Diseases | Crohn Disease | Ulcerative ColitisAustralia
-
Purdue UniversityCompletedDiet ModificationUnited States
-
Azienda Ospedaliera Specializzata in Gastroenterologia...Unknown
-
Instituto Nacional de Cardiologia Ignacio ChavezRecruitingRheumatoid Arthritis | Inflammatory Response | Diet, HealthyMexico
-
University of South CarolinaPrisma Health-UpstateWithdrawnObesity | Overweight | Infertility | Polycystic Ovarian SyndromeUnited States
-
Region Örebro CountyGöteborg University; Swedish University of Agricultural SciencesCompleted